A guide for easy- and difficult-to-treat hypertension

被引:17
|
作者
Schmieder, Roland E. [1 ]
Volpe, Massimo [2 ,3 ]
Waeber, Bernard [4 ]
Ruilope, Luis M. [5 ,6 ]
机构
[1] Univ Hosp Erlangen, Dept Hypertens & Nephrol, Erlangen, Germany
[2] Univ Roma La Sapienza, St Andrea Hosp, Clin & Mol Med Dept, Cardiol Unit, I-00185 Rome, Italy
[3] IRCCS Neuromed, Pozzilli, Italy
[4] CHU Vaudois, Div Physiopathol Clin, CH-1011 Lausanne, Switzerland
[5] Hosp 12 Octubre, Hypertens Unit, E-28041 Madrid, Spain
[6] Univ Autonoma Madrid, Dept Publ Hlth & Prevent Med, Madrid, Spain
关键词
Hypertension; Treatment algorithm; Renal denervation; RENAL SYMPATHETIC DENERVATION; FIXED-DOSE COMBINATIONS; HIGH-BLOOD-PRESSURE; DOUBLE-BLIND; HIGH-RISK; BARORECEPTOR STIMULATION; RESISTANT HYPERTENSION; OLMESARTAN MEDOXOMIL; AMLODIPINE; THERAPY;
D O I
10.1016/j.ijcard.2013.12.125
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Although the blood pressure (BP) of many patients can be controlled using standard combinations, treatment of hypertension frequently represents a clinical challenge to the primary care physician. This article will review best practices for managing patients with easy-and difficult-to-treat hypertension, including preferred antihypertensive combinations, optimizing adherence and persistence, recognizingwhite-coat hypertension, and intensifying therapy for treatment-resistant patients. Each physicianmust decide based on his or her own level of experience at what point a patient becomes too challenging and would benefit fromreferral to a hypertension specialist for more intensive management and to complete the exclusion of secondary forms of arterial hypertension. With intensive pharmacotherapy, many patients with difficult-to-treat hypertension can achieve BP control. If it fails, interventional strategies (e. g., renal denervation) are a valid option to get BP controlled. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:17 / 22
页数:6
相关论文
共 50 条
  • [21] Could Difficult-to-treat Hypertension Be a Predictor of Bad Outcome in Ischemic Stroke?
    Machado, Pedro Colla
    Zurru, Maria C.
    Luzzi, Ariel
    Brescacin, Laura
    Alonzo, Claudia
    Camera, Luis
    Waisman, Gabriel
    Cristiano, Edgardo
    STROKE, 2015, 46
  • [22] Using induced sputum cell counts to guide management of difficult-to-treat asthmatics
    Murthy, Mithun
    Scanlan, Julie
    Niven, Robert
    Scott, Stephen
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [23] Management of difficult-to-treat depression with anxiety
    Papakostas, George
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 : 324 - 324
  • [24] Systematic assessment of difficult-to-treat asthma
    Robinson, DS
    Campbell, DA
    Durharm, SR
    Pfeffer, J
    Barnes, PJ
    Chung, KF
    EUROPEAN RESPIRATORY JOURNAL, 2003, 22 (03) : 478 - 483
  • [25] Olanzapine and fluoxetine in difficult-to-treat depressions
    Dubé, S
    Corya, SA
    Tollefson, GD
    Andersen, SW
    Risser, RC
    Case, M
    Briggs, SD
    Tohen, M
    JOURNAL OF AFFECTIVE DISORDERS, 2004, 78 : S48 - S49
  • [26] Innovative approaches for difficult-to-treat populations
    Fenby, BL
    PSYCHIATRIC SERVICES, 1998, 49 (04) : 544 - 545
  • [27] Management of difficult-to-treat inhibitor patients
    Giangrande, P. L. F.
    Escobar, M. A.
    HAEMOPHILIA, 2010, 16 : 52 - 57
  • [28] CHEMOTHERAPEUTIC POSSIBILITIES IN DIFFICULT-TO-TREAT INFECTIONS
    WILLIAMS, JD
    INFECTION, 1980, 8 (06) : 309 - 313
  • [29] Management of Difficult-to-Treat Atopic Dermatitis
    Arkwright, Peter D.
    Motala, Cassim
    Subramanian, Hamsa
    Spergel, Jonathan
    Schneider, Lynda C.
    Wollenberg, Andreas
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2013, 1 (02): : 142 - 151
  • [30] An inflamed subtype of difficult-to-treat depression
    Suneson, Klara
    Grudet, Cecile
    Ventorp, Filip
    Malm, Johan
    Asp, Marie
    Westrin, Asa
    Lindqvist, Daniel
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2023, 125